Biotech
Arthrosi Therapeutics
Arthrosi Therapeutics raises $153M Series E at $800M valuation
$153M
Total Raised
Series E
Latest Round
2019
Founded
120+
Employees
San Diego, CA
1 min read
Quick Facts
Valuation
$800M
Latest Round Size
$153M
Latest Round Date
October 2025
Arthrosi Therapeutics: Series E Funding Round
Arthrosi Therapeutics has successfully raised $153M in Series E funding, reaching a valuation of $800M.
Company Overview
Developing next-generation gout treatment drug for chronic conditions
Funding Details
The Series E round was led by New Enterprise Associates, with participation from RA Capital.
Company Information
- Headquarters: San Diego, CA
- Founded: 2019
- Employees: 120+
- Category: Biotech
Investment
Arthrosi Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- New Enterprise Associates: Verified investor in Series E
- RA Capital: Verified investor in Series E
Key Investors
New Enterprise Associates
Lead Investor
Verified investor in Series E
RA Capital
Investor
Verified investor in Series E
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min readβ’$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min readβ’$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min readβ’$250M